Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program

Malcolm A. Smith, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, John M. Maris, Stephen T. Keir, Christopher L. Morton, C. Patrick Reynolds, Min H. Kang, Janine Arts, Tarig Bashir, Michel Janicot, Raushan T. Kurmasheva, Peter J. Houghton

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC 50 (0.85μM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53.

Original languageEnglish (US)
Pages (from-to)329-332
Number of pages4
JournalPediatric Blood and Cancer
Issue number2
StatePublished - Aug 2012
Externally publishedYes


  • Developmental therapeutics
  • JNJ-26854165
  • Preclinical testing

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program'. Together they form a unique fingerprint.

Cite this